<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198666">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504348</url>
  </required_header>
  <id_info>
    <org_study_id>IICT-FK506-01</org_study_id>
    <nct_id>NCT00504348</nct_id>
  </id_info>
  <brief_title>Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus</brief_title>
  <acronym>IMPPACT</acronym>
  <official_title>An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Medical and Dental University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Medical Association</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tokyo Medical and Dental University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the combination treatment
      of tacrolimus and corticosteroid in polymyositis/dermatomyositis patients with interstitial
      pneumonitis with comparison against corticosteroid-treated historical controls.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Interstitial Pneumonitis</condition>
  <condition>Polymyositis</condition>
  <condition>Dermatomyositis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.</description>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Experimental treatment group

          1. Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of
             Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed
             by Sontheimer et al

          2. High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a
             radiologist. If consolidation is the only abnormal findings, the patient must have
             pathologically documented evidence of interstitial pneumonitis of other histological
             type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing
             pneumonia (the patient could have more than one histological type including
             cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia)

          3. Meet two or more of the following criteria (must include 1) 1. Serum KL-6 above the
             upper normal limit 2. Presence of dyspnea on exertion (grade 2 on the Magnitude of
             Task component of the Mahler Modified Dyspnea Index 3. PaO2 of less than 80 mmHg
             while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2 4.
             Vital capacity &lt; 80% predicted, or diffusing capacity for carbon monoxide &lt; 65%
             predicted 5. Meet at least one of the following condition over the 12-week period (84
             days) prior to the initiation of the study drug

               -  Decrease in either % forced vital capacity or % diffusing capacity for carbon
                  monoxide of 10% or more

               -  Worsening of interstitial pneumonitis findings by chest CT, confirmed by a
                  radiologist

          4. 16 to 74 years of age

        Historical control group

          1. Diagnosis of definite or probable polymyositis or dermatomyositis by criteria of
             Bohan et al, or of clinically-amyopathic dermatomyositis by the definition proposed
             by Sontheimer et al

          2. High-resolution CT findings consistent with interstitial pneumonitis, confirmed by a
             radiologist. If consolidation is the only abnormal findings, the patient must have
             pathologically documented evidence of interstitial pneumonitis of other histological
             type than cryptogenic organizing pneumonia/bronchiolitis obliterans organizing
             pneumonia (the patient could have more than one histological type including
             cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia)

          3. Meet two or more of the following criteria (must include 1) 1. Serum KL-6 above the
             upper normal limit 2. Presence of dyspnea on exertion (grade 2 on the Magnitude of
             Task component of the Mahler Modified Dyspnea Index 3. PaO2 of less than 80 mmHg
             while breathing ambient air at rest, not accompanied by abnormal increase of PaCO2 4.
             Vital capacity &lt; 80% predicted, or diffusing capacity for carbon monoxide &lt; 65%
             predicted 5. Meet at least one of the following condition over the 12-week period (84
             days) prior to the initiation of the study drug

               -  Decrease in either % forced vital capacity or % diffusing capacity for carbon
                  monoxide of 10% or more

               -  Worsening of interstitial pneumonitis findings by chest CT, confirmed by a
                  radiologist

          4. Use of corticosteroids at doses equivalent to between 0.6 to 1.0mg/kg/day of
             prednisolone for 14 days or longer to treat interstitial pneumonitis on or after the
             day when the inclusion criteria (3) was met (up to two courses of pulse IV
             corticosteroid therapy within the first 28 days are allowed)

          5. 16 to 74 years of age

        Exclusion Criteria:

        Experimental treatment group

          1. Use of corticosteroids at doses equivalent to or higher than prednisolone
             0.6mg/kg/day within 4 weeks (28 days) prior to the initiation of the study drug

          2. Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days)
             prior to the initiation of the study drug

          3. Could not exclude the following conditions on clinical ground: drug-induced
             pneumonitis, occupational lung disease, hypersensitivity pneumonitis,
             radiation-induced lung injury

          4. Presence of end-stage interstitial pneumonitis as identified on the basis of a vital
             capacity &lt; 45% predicted, diffusing capacity for carbon monoxide &lt; 30% predicted, or
             lung CT with predominantly honeycombing appearance

          5. Presence of pancreatitis

          6. Presence of diabetes mellitus with the exception of glucocorticoid-induced one that
             is well-controlled (HbA1c &lt; 6.5%)

          7. Serum creatinine of 1.5 mg/dL or above

          8. Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper
             limit of normal) with the exception of the one that is considered to be due to
             myositis and is accompanied by the elevation of muscle enzymes above the upper limit
             of normal

          9. Serum potassium above the upper limit of normal

         10. Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart
             failure, or pulmonary hypertension requiring treatment

         11. Presence or history of malignancy with the exception of those without relapse off
             treatment for 5 years or longer

         12. Presence of serious active infection

         13. Presence of active hepatitis B, hepatitis C, or HIV infection

         14. History of severe drug hypersensitivity reaction

         15. Patients who are pregnant or breast-feeding, or patients who intend to or whose
             spouses intend to conceive during the course of the study, including the follow-up
             period

         16. Participation in another clinical trial or post-marketing clinical study within 26
             weeks (182 days) prior to screening

         17. Other medical condition which, in the investigator`s judgment, may be associated with
             increased risk to the subject or may interfere with study assessments or outcomes

        Historical control group

          1. Use of immunosuppressive agents other than corticosteroids within 12 weeks (84 days)
             prior to or 2 weeks (14 days) after the corticosteroid treatment as defined by the
             inclusion criteria (4) is initiated

          2. Could not exclude the following conditions on clinical ground: drug-induced
             pneumonitis, occupational lung disease, hypersensitivity pneumonitis,
             radiation-induced lung injury

          3. Presence of end-stage interstitial pneumonitis as identified on the basis of a vital
             capacity &lt; 45% predicted, diffusing capacity for carbon monoxide &lt; 30% predicted, or
             lung CT with predominantly honeycombing appearance

          4. Presence of pancreatitis

          5. Presence of diabetes mellitus with the exception of glucocorticoid-induced one that
             is well-controlled (HbA1c &lt; 6.5%)

          6. Serum creatinine of 1.5 mg/dL or above

          7. Presence of liver dysfunction (AST(GOT) or ALT (GPT) greater than 2.5 times the upper
             limit of normal) with the exception of the one that is considered to be due to
             myositis and is accompanied by the elevation of muscle enzymes above the upper limit
             of normal

          8. Serum potassium above the upper limit of normal

          9. Presence of ischemic heart disease, arrhythmia requiring treatment, congestive heart
             failure, or pulmonary hypertension requiring treatment

         10. Presence or history of malignancy with the exception of those without relapse off
             treatment for 5 years or longer

         11. Presence of serious active infection including active hepatitis B, hepatitis C, or
             HIV infection

         12. Other medical condition which, in the investigator`s judgment, may be associated with
             increased risk to the subject or may interfere with study assessments or outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Miyasaka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokyo Medical and Dental University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Minami Medical Center</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center of Japan</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital of Medicine and Dentistry</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 28, 2010</lastchanged_date>
  <firstreceived_date>July 19, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Nobuyuki Miyasaka, MD, PhD, Professor and Chairman</name_title>
    <organization>Dept of Medicine and Rheumatology, Tokyo Medical and Dental University</organization>
  </responsible_party>
  <keyword>Interstitial pneumonitis</keyword>
  <keyword>Polymyositis</keyword>
  <keyword>Dermatomyositis</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Interstitial pneumonitis associated with polymyositis or dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatomyositis</mesh_term>
    <mesh_term>Polymyositis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
